Buscar resultados de ensayos clínicos
Diffuse Cutaneous Systemic Sclerosis - 25 Studies Found
Estado | Estudiar |
Active, not recruiting |
Nombre del estudio: A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis Condición: Diffuse Cutaneous Systemic Sclerosis Fecha: 2014-06-03 Intervenciones:
|
Completed |
Nombre del estudio: Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis Condición: Early Diffuse Cutaneous Systemic Sclerosis Fecha: 2014-12-22 Intervenciones:
|
Recruiting |
Nombre del estudio: Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis Condición:
Fecha: 2015-06-30 Intervenciones: |
Active, not recruiting |
Nombre del estudio: Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis Condición: Diffuse Cutaneous Systemic Sclerosis Fecha: 2015-06-04 Intervenciones:
|
Completed |
Nombre del estudio: Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis Condición: Systemic Sclerosis Fecha: 2012-08-15 Intervenciones: Drug: Belimumab Belimumab (Benlysta®) decreases B-Cell survival and has been FDA approved for the t |
Completed |
Nombre del estudio: Mycophenolate Mofetil in Systemic Sclerosis Condición: Diffuse Cutaneous Systemic Sclerosis Fecha: 2007-02-07 Intervenciones: Drug: Mycophenolate Mofetil Mycophenolate 3000 mg each day |
Completed |
Nombre del estudio: AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis Condición: Systemic Sclerosis Fecha: 2008-10-07 Intervenciones:
|
Not yet recruiting |
Nombre del estudio: Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis Condición: Scleroderma, Systemic Fecha: 2017-01-31 Intervenciones:
|
Withdrawn |
Nombre del estudio: A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc) Condición: Scleroderma Fecha: 2015-10-26 Intervenciones:
|
Recruiting |
Nombre del estudio: Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension Condición:
|